Relypsa For ED Acute Hyperkalemia Control and Reduction (REDUCE)
Status:
Completed
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
The Investigator hypothesize that a single dose of patiromer will lower serum potassium
levels in less than 6hrs. Since a dosage of 30g/day for a period of 4 weeks has been studied
in at least two multicenter randomized controlled trials, the Investigator further
hypothesize that a single dose of 25.2g of patiromer will be well tolerated in hyperkalemic
patients in the Emergency Department setting. The FDA approved dosage of 25.2g is appropriate
for this study because the research staff will enroll patients with moderate (K greater than
6 mEq/L) to severe hyperkalemia, and the higher dosage has typically been used in this
population for more effective control.